首页> 美国卫生研究院文献>Oncotarget >IgH gene rearrangements as plasma biomarkers in Non-Hodgkins Lymphoma patients
【2h】

IgH gene rearrangements as plasma biomarkers in Non-Hodgkins Lymphoma patients

机译:IgH基因重排作为非霍奇金淋巴瘤患者血浆生物标志物

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

New biomarkers with improved accuracy could be helpful for monitoring disease in patients with Non-Hodgkin's lymphomas (NHL). Towards this end, we have explored the feasibility of identifying the sequence of rearranged IgH genes using next-generation sequencing, then using PCR to detect specific rearranged DNA fragments in patients' plasma. By capturing and sequencing the IgH genomic regions (IgCap), we were able to detect and precisely determine the sequence of rearranged IgH loci in the tumors of three NHL patients. Moreover, circulating rearranged DNA fragments could be identified in the plasma of all three patients. Even in cases wherein tumor biopsies were unavailable, we were able to use the IgH capture approach to identify rearranged DNA loci in the plasma of 8 of 14 patients. IgCap may enable a more informed management of selected patients with NHL and other B-cell malignancies in the future.
机译:准确性更高的新型生物标志物可能有助于监测非霍奇金淋巴瘤(NHL)患者的疾病。为此,我们探索了使用下一代测序鉴定重排IgH基因序列的可行性,然后使用PCR检测患者血浆中特定的重排DNA片段。通过捕获和测序IgH基因组区域(IgCap),我们能够检测并精确确定三名NHL患者肿瘤中重排的IgH基因座的序列。而且,可以在所有三名患者的血浆中鉴定出循环重排的DNA片段。即使在无法进行肿瘤活检的情况下,我们也能够使用IgH捕获方法来识别14例患者中8例血浆中的重排DNA位点。 IgCap可能会在将来对选定的NHL和其他B细胞恶性肿瘤患者进行更明智的管理。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号